Famotidine and Buspirone Drug-Drug Interaction
No clinically significant pharmacokinetic or pharmacodynamic interaction between famotidine and buspirone is documented in available prescribing information. [1] Buspirone pharmacokinetic drug interactions are primarily driven by CYP3A4 inhibition or induction, while famotidine labeling highlights interaction risk primarily through gastric pH–dependent absorption and a specific CYP1A2 substrate interaction. [1], [2]
Interaction Evidence in Buspirone Labeling
Buspirone is described as being metabolized primarily by CYP3A4. [1] The buspirone label identifies pharmacokinetic interactions with multiple CYP3A4 inhibitors (e.g., verapamil, diltiazem, erythromycin, itraconazole) that increase buspirone exposure. [1] The buspirone label identifies cimetidine as increasing buspirone Cmax and T max with minimal effects on AUC. [1] Famotidine is not listed among the specific interacting drugs in the buspirone label sections describing known drug interactions. [1]
Interaction Mechanisms Relevant to Famotidine
Famotidine labeling emphasizes reduced systemic exposure of concomitant drugs that depend on gastric pH for absorption. [2] Famotidine labeling also identifies a contraindicated/avoid interaction with tizanidine based on CYP1A2 substrate involvement. [2] Famotidine labeling does not identify CYP3A4 inhibition as a relevant mechanism for drug-drug interactions. [2]
Practical Clinical Implications
Coadministration of famotidine with buspirone is not expected to produce a CYP3A4-mediated change in buspirone exposure based on the interaction mechanisms described for famotidine. [1], [2] Monitoring for buspirone-related adverse effects (e.g., dizziness, sedation) remains appropriate with any additional interacting medication that increases buspirone exposure via CYP3A4 inhibition. [1]
When Additional Caution May Be Needed
Additional caution is indicated when buspirone is coadministered with known strong CYP3A4 inhibitors or inducers, since buspirone exposure may substantially increase or decrease. [1] Caution is also indicated for comedications whose absorption is gastric pH dependent when used with famotidine. [2]
Conclusion
Available prescribing information does not support a clinically significant pharmacokinetic or pharmacodynamic interaction between famotidine and buspirone. [1], [2]